PCSK9 Infographics

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in cholesterol homeostasis and inflammation, platelet activation, and atherosclerosis disease progression.
This infographic presents the physiological functions and molecular features that make PCSK9 an attractive therapeutic target for cardiovascular diseases.
Various strategies for targeting PCSK9 and clinical trials involving PCSK9-inhibitors are also delineated.

First published: March 21, 2024  

Our latest infographic discusses the role of combination therapy in lowering lipids in patients with ASCVD.

First published: July 20, 2023  

This infographic summarizes the key take home messages of the World Heart Federation’s Cholesterol Roadmap.

First published: March 3, 2023  

Check out and download our latest infographic based on the 2022 Expert Consensus Decision Pathway by the American College of Cardiology – Role of Nonstatin Therapies in Lowering LDL-Cholesterol during ASCVD Risk Management.

First published: November 3, 2022  

Novel pharmacological interventions targeting lipids can lower the incidence of dyslipidaemia triggered cardiovascular events. Check out and download our latest infographic providing insights into evolution of lipid-lowering therapeutics and status of novel therapeutics highlighting their development, safety, and efficacy.

First published: August 8, 2022